astrazeneca cns ron polinsky vice president ta the opportunity h devastating disability immense cost burden huge unmet medical need decade of brain fastest growing segment 1998 estimated 2010 19bn 50bn neurological psycho therapeutics major market potential in psychiatry & neurology broad coverage therapeutic area depression anxiety disorders schizophrenia bipolar sleep addiction eating acute stroke multiple sclerosis migraine movement dementia epilepsy overactive bladder head trauma strategic targets enia i compounds development brands on disabling disease common up to 15 attacks are unpredictable sufferers rapid reliable consistent relief any time source ims health 1999 q2 q3 q4 q1 97 98 99 0 20 40 60 80 100 120 m zomig naratriptan rizatriptan countries included usa uk germany holland sweden finland mexico outselling effective management helps physicians improve care simple clinically validated questionnaire relates illness severity treatment needs disc stratified
